首页> 外国专利> DESIGN, SYNTHESIS CHARACTERIZATION AND BIOLOGICAL EVALUATION OF SOME NOVEL HETERO CYCLIC DERIVATIVES AS ANTI-TUBERCULAR AGENTS

DESIGN, SYNTHESIS CHARACTERIZATION AND BIOLOGICAL EVALUATION OF SOME NOVEL HETERO CYCLIC DERIVATIVES AS ANTI-TUBERCULAR AGENTS

机译:一些新型抗杂环化合物的设计,合成表征及生物学评价

摘要

Abstract In the present work, some Novei Heterocyclic derivatives were synthesized, characterized and evaluated for anti-tubercular activity. The compounds were synthesized by stirring and reflux condensation method. The chemical structures of synthesized compound were confirmed by IR, NMR and MASS spectral analysis. Crystals suitable for X-ray crystallographic studies for one derivative was performed and confirmed. The synthesized compounds were initially investigated for in-viiro anti-tubercular activity (MABA- Micro-liter Alamar Blue Assay). The concentrations at which the compounds are sensitive were determined and found that they are sensitive at lower concentration. Synthesized compounds which exhibit promising In-vitro anti-tubercular activity were subjected to acute toxicity studies in order to find out the toxicity induced mortality and other behavioral changes. Further with the acute toxicity results, and in-vitro anti-tubercular activity rankings top 3 compounds selected and subjected for in-vivo anti-tubercular activity study.
机译:摘要本文合成了一些诺维杂环衍生物,并对其抗结核活性进行了表征和评价。通过搅拌和回流缩合方法合成化合物。通过IR,NMR和MASS光谱分析证实了合成化合物的化学结构。进行并确认了适用于一种衍生物的X射线晶体学研究的晶体。最初对合成的化合物的体外抗结核活性进行了研究(MABA-微升Alamar Blue分析法)。确定化合物敏感的浓度,发现它们在较低浓度下敏感。对表现出有希望的体外抗结核活性的合成化合物进行急性毒性研究,以发现毒性引起的死亡率和其他行为改变。进一步的急性毒性结果和体外抗结核活性位居前三位,并进行了体内抗结核活性研究。

著录项

  • 公开/公告号IN201741029944A

    专利类型

  • 公开/公告日2018-08-10

    原文格式PDF

  • 申请/专利权人

    申请/专利号IN201741029944

  • 申请日2017-08-24

  • 分类号G06Q50;

  • 国家 IN

  • 入库时间 2022-08-21 12:51:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号